Effects of ibuprofen on skeletal muscle adaptation to resistance exercise in young healthy adults.

The effects of COX-inhibiting drugs on skeletal muscle adaptations to resistance exercise in healthy adults.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-004872-47-SE

Enrollment

Unknown

Registered

2015-05-22

Start date

2015-07-20

Completion date

Unknown

Last updated

2016-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human skeletal muscle adaptations to resistance exercise (non-disease related).

Interventions

Trade Name: Ipren (Ibuprofen 400 mg) Product Name: Ipren (Ibuprofen 400 mg) Pharmaceutical Form: Tablet INN or Proposed INN: IBUPROFEN Current Sponsor code: NSAID2015 Concentration unit: mg milligram(

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: men / women age 18-35 Physically active 1-4 hrs per week Signed informed consent Deemed healthy after anamnesis and health declaration Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Lower leg injury Sensitivity to any of the prescribed medications Ulcer or gastrointestinal problems Liver dysfunction Autoimmune disease Kidney disease Hypertension Established cardiovascular disease Anamnesia of substantial bleedings Consumption of medications that counteracts or act synergistically with the prescribed drugs Takes part in another research study

Design outcomes

Primary

Measure	Time frame
Main Objective: To study the effects of Ibuprofen on skeletal muscle adaptations to resistance exercise (see study protocol).;Secondary Objective: Not applicable;Primary end point(s): Muscle volume Muscle strength (force) ;Timepoint(s) of evaluation of this end point: Before and after 8 weeks of training	—

Secondary

Measure	Time frame
Secondary end point(s): Muscle gene and protein expression;Timepoint(s) of evaluation of this end point: Before and after acute exercise, as well as before and after training (see protocol)	—

Countries

Sweden

Contacts

Public ContactTommy Lundberg

Karolinska Institutet, Department of Laboratory Medicine, Clinical Physiology C1:82,Karolinska Univ. Hosp., Huddinge

tommy.lundberg@ki.se+46858586771

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026